High expression of EZH2 promotes advanced non‐small cell lung cancer (NSCLC) resistance to cisplatin,41 and EZH2 has been suggested as a predictive marker for tamoxifen therapy in metastatic breast cancer.42 The gene discussed is EZH2; the disease is non-small cell lung carcinoma.